US research roundup: Eli Lilly, Netflix, Zscaler
NFLX•Analysts revised ratings and price targets on US-listed companies on Wednesday. Leerink Partners raised Eli Lilly’s target to $1,316 from $1,309, Canaccord Genuity cut Netflix’s to $110 from $125, and D.A. Davidson initiated Zscaler at neutral with a $215 target.
1. Analyst actions
The roundup includes rating and price-target changes across dozens of US-listed companies. For Netflix, several firms cut targets, including Deutsche Bank to $93 from $95, Bernstein to $80 from $95, and Morgan Stanley to $77 from $80. Needham also cut its rating to hold from buy.
2. Other notable moves
D.A. Davidson initiated coverage of Zscaler with a neutral rating and a $215 price target. Leerink Partners raised its Eli Lilly target to $1,316 from $1,309. The roundup also reports a range of target changes for companies including 3M, Ally Financial, Braze, Capital One and General Motors.
